Dozens of biotech companies are ‘free’ for investors’ taking

They’re trading at less than net cash, making them bargains — and also risky, so buyer beware, says Michael Brush.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.